Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.75 |
| ▸ | AKT2 | P31751 | 20/20 | 0.75 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 0.75 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.69 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191301 | 1.00 | AKT1 (0.75) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL4982283 | 0.89 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL15390637 | 0.89 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16617460 | 0.89 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3948393 | 0.89 | AKT1 (0.82) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL22375150 | 0.89 | AKT1 (0.71) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL190998 | 0.88 | AKT1 (0.57) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL31216120 | 0.88 | AKT1 (0.70) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL1738836 | 0.88 | AKT1 (0.68) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL191211 | 0.88 | AKT1 (0.68) | AKT1AKT2AKT3PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2025-05-15 | — | — | US | disclosed |
| CN-112898210-B | Process for preparing pyrimidinylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-4282973-A2 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3656764-B1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| CN-110590606-B | Process for preparing pyrimidylcyclopentane compounds | 豪夫迈·罗氏有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-10858324-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | GENENTECH, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3656764-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-05-27 | — | — | EP | disclosed |
| US-20200062717-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-10435378-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-9315471-B2 | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | GENETECH, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160051550-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-9150548-B2 | Combinations of AKT inhibitor compounds and vemurafenib, and methods of use | GENENTECH, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150274677-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20140275106-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2402325-A2 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | Array Biopharma, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2399909-A1 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors | Array Biopharma, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2049501-B1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274677-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL-CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CD, AKT1S1 | AKT1 5/4885AKT2 4/4885AKT3 7/4885 |
| US-10858324-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-10435378-B2 | Processes for the preparation of pyrimidinylcyclopentane compounds | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | PIK3CA, PIK3CD, PIK3CG | AKT1 10/4885AKT2 6/4885AKT3 20/4885 |
| US-20140275106-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE | BRAF, AKT2, PIK3CA | AKT1 4/4885AKT2 2/4885AKT3 7/4885 |
| US-20160051550-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | AKT1, AKT2, MTOR | AKT1 1/4885AKT2 2/4885AKT3 5/4885 |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-20200062717-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS | DHPS, TYMP, DHFR | AKT1 3267/4885AKT2 3039/4885AKT3 3982/4885 |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.